Search

Displaying results 4431 - 4440 of 8974 in total
  1. Drug

    Crofelemer

    go.drugbank.com/drugs/DB04941
    ApprovedInvestigational

    It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Suramin

    go.drugbank.com/drugs/DB04786
    Investigational

    (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin®. … It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca.

  3. Target

    Polycomb protein EED

    go.drugbank.com/bio_entities/BE0012001
    TargetHumans

    The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. … Component of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene.

    Synonyms: WAIT-1
  4. Drug

    Picoplatin

    go.drugbank.com/drugs/DB04874
    Investigational

    It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription. … Picoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with solid tumors.

  5. Drug

    Tolterodine

    go.drugbank.com/drugs/DB01036
    ApprovedInvestigational

    Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

    Categories: Drugs for Urinary Frequency and Incontinence
  6. Drug

    Pinacidil

    go.drugbank.com/drugs/DB06762
    Approved

    Pinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance. … This drug has been discontinued by the FDA.

  7. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care. … CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy.

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Bevirimat

    go.drugbank.com/drugs/DB06581
    Investigational

    Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. … This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics.

  9. Drug

    Evofosfamide

    go.drugbank.com/drugs/DB06091
    Investigational

    TH-302 has been shown, in preclinical studies, to be both efficacious and well tolerated. … TH-302 is a novel cancer therapeutic specifically activated under the low oxygen or "hypoxic" conditions typical of solid tumor cancer cells.

  10. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].